People who have diabetes are 1.5 to two times more likely to be depressed than people in the general population, 1 and depression in people with diabetes is associated with a range of poor outcomes, including higher blood glucose levels, 2 an increased risk of complication 3 and mortality rates, 4 and higher healthcare costs. In 1996 Eaton and his colleagues at Johns Hopkins published a study suggesting that Willis might have been right after all, at least when it comes to a person's risk of developing type 2 diabetes. 9 This study was followed several years later by one conducted in Japan by Kawakami and colleagues. 10 This study also supported Willis' hypothesis. In each of these studies, and in the many that followed in the next 10 years, the researchers identified a group of people who at the outset of the study did not have diabetes and divided the group into those who were depressed and those who were not depressed. The researchers then followed their subjects for a certain period of time (13 years in the Eaton study and eight years in the Kawakami study),
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Depression is also associated with smoking, another behavior known to increase a person's risk of developing diabetes. In the Insulin Resistance Atherosclerosis Study (IRAS), current smokers were almost three times as likely to develop diabetes over five years than those who had never smoked. 27 Depression is also associated with sleep disturbances, and some studies have found increased rates of diabetes in people who sleep either very little (less than five hours a night) or a lot (more than nine hours a night).
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Psycho-neurohormonal Mechanisms
Depression could also increase diabetes risk via psycho-neurohormonal mechanisms and can be seen as a stress response 'gone awry.' Stress triggers release of catecholamines, growth hormone, glucagon, and cortisol, all of which increase blood glucose levels. When a person is depressed, this release is abnormally prolonged. Depression is also associated with the hypersecretion of pro-inflammatory cytokines, which may not only increase diabetes risk by interfering with insulin action, but may also contribute to the risk of cardiovascular disease, the leading cause of death in people with diabetes.
Conclusions Regarding the Natural History of Depression and Type 2 Diabetes
There is ample evidence that being depressed may increase a person's risk of developing type 2 diabetes, at least for people who have high levels of depressive symptoms or for people who are not already at a very high risk for developing diabetes (as was the case for participants in the DPP). The fact that depression may be a risk factor for developing diabetes does not preclude the possibility that having diabetes could also increase a person's risk for being depressed. Diabetes-related distress, especially distress associated with diabetes complications, may increase depression risk. 22, 31 This may also, in part, explain the higher recurrence rates and longer duration of major depressive disorder (MDD) and depressive symptoms among those with diabetes compared with individuals who do not have diabetes. DPP participants were randomized to one of three treatment arms when they entered the study: an arm that took placebo metformin (PLB), an arm that took active metformin (MET), and an arm that was offered an intensive lifestyle program (ILS).
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Data from the DPP strongly suggest that antidepressant use is a diabetes risk factor in individuals who are already at a very high risk for developing diabetes, while elevated depressive symptom scores were not associated with an increased diabetes risk (see Figure 1) . 
Antidepressant Use and Diabetes Risk
The DPP results are probably most notable for finding an increased diabetes risk in PLB and ILS participants who were taking antidepressant medication.
Two recent studies also assessed the association between antidepressant use and diabetes risk. One study 34 found no significant association, but the study did not incorporate a definitive assessment of diabetes status. The other study 35 found an increased risk of developing diabetes among individuals taking selective serotonin re-uptake inhibitors (SSRIs) in addition to tricyclic antidepressants (TCA) compared with those taking TCA alone, but the study did not include individuals taking no antidepressants, so the authors could not assess the diabetes risk associated with taking any antidepressant.
In the DPP, 78% of those who were taking any antidepressant were taking SSRIs or related agents, which are generally considered to have less effect on weight than TCA, with some reports that SSRIs actually contributed to weight loss 36 and improved insulin sensitivity. 37 In the DPP, SSRI use was associated with minor weight gain, and use of these agents was associated with an increased diabetes risk in the PLB and ILS arms, which was the case for use of any antidepressant.
In an effort to explain the association between antidepressant use and diabetes risk we controlled all likely mediators, including fasting glucose level, weight on entry to the study, and weight gain during the study, but the association remained significant in the PLB and ILS arms. second, the effects of these episodes would have to operate after the symptoms had resolved, since DPP participants taking antidepressants did not have elevated symptoms on entry to the study or during the study. It is also possible that antidepressant users experience some effect of depression not detected by the questionnaire we used to assess depression.
Although there is no obvious explanation for the findings that antidepressant use was not associated with diabetes risk in the MET arm, the finding is similar to a previous DPP report that metformin treatment not only reduced the risk of developing diabetes compared with placebo treatment, but it also eliminated the predictive effect of BMI on diabetes risk.
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Research Implications
The DPP finding of an association between antidepressant use and diabetes risk requires confirmation, ideally in studies examining the risk associated with different classes of antidepressant and even specific agents. These studies will require large populations to generate sufficient sample sizes; prescription databases could be one source. If these studies yield the same results as the DPP study, further studies should attempt to determine whether the use of these agents is an independent diabetes risk factor or whether antidepressant use is a marker for depression severity or chronicity. Studies comparing antidepressant-associated diabetes risk with psychotherapy-associated diabetes risk would also be useful.
Clinical Implications
If future studies show that antidepressant use is an independent diabetes risk factor, clinicians will need to keep this in mind when treating patients who are depressed and at high risk for developing diabetes. If some antidepressants are found to have relatively little risk of increasing rates of diabetes, these agents should be used rather than agents associated with higher diabetes risk. Psychological treatment could also help patients avoid the iatrogenic effects of antidepressants, although in many instances resources for such treatment are very limited. We do know that cognitive behavioral therapy, one form of psychological treatment for depression, was associated with improved glycemic control in patients who had high glycated hemoglobin (HbA 1c ) levels. 39 This suggests a potential benefit for patients at risk of developing diabetes. Clinicians should also try to determine the depression status of patients who are at risk for developing diabetes, since many studies other than the DPP suggest that elevated symptoms are a diabetes risk factor. Likely depression status can be determined by asking patients questions about the two cardinal symptoms of depression. These questions and a scoring algorithm appear in Table 2 . Patients with a combined total score of three or more on the two questions could well be depressed, and further screening and assessment is warranted.
Public Health Implications
Applying current estimates of the number of people in the US who have prediabetes (57 million with impaired glucose tolerance or impaired fasting glucose), and estimates of the prevalence of antidepressant use among adults in the US (at least 10%), it would seem that almost six million people in the US have pre-diabetes and are taking antidepressants. This is a fairly large number of people, and if future research confirms that antidepressants are an independent risk factor for type 2 diabetes, efforts to minimize the potentially negative effects of these agents on glycemic control should be pursued. The DPP findings suggest that the use of metformin might be beneficial. ■ 
